Other
Interest Income, Other
Royalty Pharma Interest Income, Other decreased by 11.9% to $6.23M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 44.8%, from $11.29M to $6.23M. Over 3 years (FY 2022 to FY 2025), Interest Income, Other shows a downward trend with a -24.6% CAGR.
Analysis
StatementIncome Statement
SectionOther
CategoryOther
SignalContext dependent
VolatilityModerate
First reportedQ1 2022
Last reportedQ1 2026May 6, 2026
How to read this metric
Fluctuations are generally immaterial but may indicate changes in non-core financial activities or accounting adjustments.
Detailed definition
This represents miscellaneous interest income that does not fall into primary categories like loans or securities. It of...
Peer comparison
Varies significantly by bank based on accounting policies for non-core interest items.
Metric ID:
other_interest_income_otherHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $19.58M | $19.58M | $19.58M | $19.58M | $16.70M | $25.65M | $23.44M | $6.50M | $7.42M | $13.38M | $17.51M | $9.04M | $11.29M | $8.33M | $6.90M | $7.07M | $6.23M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -14.7% | +53.6% | -8.6% | -72.3% | +14.1% | +80.4% | +30.8% | -48.4% | +24.9% | -26.2% | -17.1% | +2.4% | -11.9% |
| YoY Change | — | — | — | — | -14.7% | +31.0% | +19.7% | -66.8% | -55.6% | -47.8% | -25.3% | +39.0% | +52.2% | -37.8% | -60.6% | -21.8% | -44.8% |
Range$6.23M – $25.65M
CAGR-24.9%
Avg YoY Growth-17.9%
Median YoY Growth-25.3%
Interest Income, Other at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's interest income, other?
- Royalty Pharma (RPRX) reported interest income, other of $6.23M in Q1 2026.
- How has Royalty Pharma's interest income, other changed year-over-year?
- Royalty Pharma's interest income, other decreased by 44.8% year-over-year, from $11.29M to $6.23M.
- What is the long-term trend for Royalty Pharma's interest income, other?
- Over 3 years (2022 to 2025), Royalty Pharma's interest income, other has grown at a -24.6% compound annual growth rate (CAGR), from $78.34M to $33.59M.
- What does interest income, other mean?
- Other miscellaneous interest income not categorized elsewhere.